Author(s): Aun C, Flynn PJ, Richards J, Major E
Abstract Share this page
Abstract In a randomised cross-over trial, midazolam, a new water soluble benzodiazepine was compared with the conventional diazepam preparation (Valium) in 34 patients aged 16-45 years who were undergoing outpatient conservation dentistry. Midazolam hydrochloride (0.17 mg/kg) was virtually free of venous complications and showed advantages over diazepam (0.32 mg/kg) in providing a faster onset of action, higher incidence of amnesia and more rapid recovery. Midazolam produced a higher incidence of respiratory side effects hiccough (17.6\% compared with 2.9\%), brief apnoea following induction (11.8\% compared with 5.8\%), and airway obstruction during maintenance (8.8\% compared with 0\%). These may be related to the greater potency of midazolam as suggested by the smaller total dose required. Cardiovascular changes and operating conditions were similar.
This article was published in Anaesthesia
and referenced in Journal of Microbial & Biochemical Technology